

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number
WO 2004/024197 A1

(51) International Patent Classification⁷: **A61L 15/44**,
15/28, 15/22, 26/00, 31/16, 31/04

North Yorkshire BD23 2QX (GB). **GREGORY, Sarah-Jayne** [GB/GB]; 58 Moorland Crescent, Guiseley, Leeds LS20 9EF (GB).

(21) International Application Number:
PCT/GB2003/003898

(74) Agents: **JAMES, Anthony, Christopher, W., P. et al.**; Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA (GB).

(22) International Filing Date:
10 September 2003 (10.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0221062.3 11 September 2002 (11.09.2002) GB
60/414,381 30 September 2002 (30.09.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **JOHNSON & JOHNSON MEDICAL LIMITED** [GB/GB]; Erskine House, 68-73 Queen Street, Edinburgh EH2 4NH (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CULLEN, Breda, Mary** [GB/GB]; 7 Consort Street, Skipton, North Yorkshire BD23 1HR (GB). **ADDISON, Deborah** [GB/GB]; 2 Dovenanter Cottage, Keasden, Clapham, Via Lancaster, LA2 8HB (GB). **GREENHALGH, David** [GB/GB]; 22 Tile Close, Skipton, North Yorkshire, BD23 2LG (GB). **ESSELER, Alicia** [GB/GB]; 17B Walton Street, Skipton,

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: WOUND DRESSING MATERIALS COMPRISING COMPLEXES OF ANIONIC POLYSACCHARIDES WITH SILVER

(57) Abstract: The invention provides a wound dressing material comprising a complex of an anionic polysaccharide with silver, wherein the material comprises from about 0.1wt. % to about 3wt. % of silver. Also provided are wound dressings comprising such materials, and the use of such materials in medicine.

WOUND DRESSING MATERIALS COMPRISING COMPLEXES OF ANIONIC POLYSACCHARIDES WITH SILVER

The present invention relates to wound dressing materials comprising complexes
5 formed between anionic polysaccharides, such as oxidized regenerated cellulose (ORC), and silver, and to the uses thereof for the treatment of wounds.

Anionic polysaccharides such as alginates, hyaluronic acid and its salts, and
oxidized celluloses such as oxidized regenerated cellulose (ORC) are known for
10 use as wound dressing materials. Alginates and ORC are hemostatic when applied to a wound.

EP-A-0437095 describes the preparation of a neutralized ORC fabric by reacting
ORC with a buffered solution of a salt of a weak acid, such as sodium acetate.
15 The use of a buffered reagent is said to result in less breakdown of ORC fabrics. The neutralized ORC can support further acid-sensitive hemostatic agents such as thrombin or t-PA.

WO98/00180 describes the use of freeze-dried sponges of collagen admixed with
20 oxidized regenerated cellulose (ORC) for the treatment of chronic wounds. The mixed sponges provide enhanced healing of chronic wounds such as venous ulcers, decubitis ulcers and diabetic ulcers. The specification mentions that silver sulfadiazine or chlorhexidine may be present as an antiseptic additive.

25 GB-A-748283 describes complexes of polysaccharides with various metals, including silver. WO91/11206 describes the use of silver alginate salts in wound dressings. WO87/05517 describes silver salts of hyaluronic acid that may be used as or in antimicrobial wound dressings.

30 WO02/43743 describes wound dressings comprising a silver salt of an anionic polysaccharide, and further comprising a substance to improve the photostability of the silver salt. The stabilising substance may include ammonia, ammonium

salts, thiosulphates, chlorides and/or peroxides. In one preferred embodiment, the stabilising agent is aqueous ammonium chloride.

The present invention provides a wound dressing material comprising a complex
5 of an anionic polysaccharide with silver, wherein the material comprises from about 0.1wt.% to about 3wt.% of silver.

The term "complex" refers to an intimate mixture at the molecular scale, preferably with ionic or covalent bonding between the silver and the polysaccharide. The
10 complex preferably comprises a salt formed between the anionic polysaccharide and Ag^+ , but it may also comprise silver clusters and/or colloidal silver metal, for example produced by exposure of the complex to light.

Preferably, the anionic polysaccharide is a polycarboxylate. Suitable anionic
15 polysaccharides include alginates, hyaluronates, pectins, carrageenans, xanthan gums, sulfated dextrans, cellulose derivatives such as carboxymethyl celluloses, and oxidized celluloses.

The term "oxidized cellulose" refers to any material produced by the oxidation of
20 cellulose, for example with dinitrogen tetroxide. Such oxidation converts primary alcohol groups on the saccharide residues to carboxylic acid groups, forming uronic acid residues within the cellulose chain. The oxidation generally does not proceed with complete selectivity, and as a result hydroxyl groups on carbons 2 and 3 are occasionally converted to the keto form. These keto units introduce an
25 alkali-labile link, which at pH 7 or higher initiates the decomposition of the polymer via formation of a lactone and sugar ring cleavage. As a result, oxidized cellulose is biodegradable and bioabsorbable under physiological conditions.

The preferred oxidized cellulose for use in the present invention is oxidized
30 regenerated cellulose (ORC) prepared by oxidation of a regenerated cellulose, such as rayon. It has been known for some time that ORC has haemostatic properties. ORC has been available as a haemostatic fabric called SURGICEL

(Registered Trade Mark of Johnson & Johnson Medical, Inc.) since 1950. This product is produced by the oxidation of a knitted rayon material.

Preferably, the anionic polysaccharide is substantially insoluble in water at pH7.

- 5 Preferably, the anionic polysaccharide has a molecular weight greater than about 20,000, more preferably greater than about 50,000. Preferably, the anionic polysaccharide is in the form of a film, or fibers having length greater than 1mm.

- 10 Preferably the amount of silver in the complex is from about 0.1% to about 50% by weight based on the weight of the anionic polysaccharide, more preferably from about 1% to about 40%, still more preferably from about 2% to about 30% by weight, and most preferably from about 5% to about 25%.

- 15 It has been found that the silver-containing complexes are suitable for use in the preparation of antimicrobial wound dressing materials. The silver confers antimicrobial properties on the wound dressing. More surprisingly, at low concentrations of about 0.1wt.% to about 3wt.%, the silver in the complex exhibits a proliferative effect on wound healing cells and therefore is expected to promote wound healing even when the complexes according to the invention are applied
- 20 directly to a wound. The oligodynamic effect of silver on cells in culture is known – this is usually regarded as affecting the growth of both bacteria and cells. It is therefore surprising to find that silver in the dressings of the present invention can have the opposite effect on certain cells of importance to wound healing.

- 25 It has also been found, surprisingly, that wound dressing materials containing the above-defined low levels of silver exhibit a surprising ability to inhibit the production of TNF- α and IL-1. This is expected to result in beneficial anti-inflammatory properties of the wound dressing materials.

- 30 The wound dressing materials according to the present invention may be in any convenient form, such as a powder, microspheres, flakes, a mat or a film.

In certain embodiments, the wound dressing material according to the present invention is in the form of a semisolid or gel ointment for topical application.

5 In certain embodiments, the wound dressing material according to the present invention is in the form of a freeze-dried or solvent-dried bioabsorbable sponge for application to a chronic wound. Preferably, the average pore size of the sponge is in the region of 10-500 μ m, more preferably about 100-300 μ m.

10 In yet other embodiments, the wound dressing material according to the present invention is in the form of a flexible film, which may be continuous or interrupted (e.g. perforated). The flexible film preferably comprises a plasticiser to render it flexible, such as glycerol.

15 Preferably, the wound dressing material is in the form of a sheet, for example a sheet of substantially uniform thickness. The area of the sheet is typically from about 1 cm² to about 400cm², and the thickness typically from about 1mm to about 10mm. The sheet may for example be a freeze-dried sponge, or a knitted, woven or nonwoven fibrous sheet or a gel sheet. Preferably, the sheet comprises less than about 15% by weight of water.

20

Preferably, the wound dressing material comprises from about 0.1wt% to 100wt% of the silver-containing complex, more preferably from about 0.1wt% to about 5wt.%, for example from about 0.2wt.% to about 2wt.%. The amount of silver in the wound dressing material is from about 0.1wt% to about 3wt.%, preferably from 25 more than about 0.1wt% to about 1wt.%, and for example from about 0.2wt.% to about 0.6wt.%, typically about 0.3wt.%. Lesser amounts of silver could give insufficient antimicrobial effect. Greater amounts of silver could give rise to antiproliferative effects on wound healing cells.

30 The wound dressing materials according to the present invention may further comprise one or more polysaccharides that have not been complexed to silver. These polysaccharides may include any one or more of the anionic polysaccharides listed above as being suitable for complexation with silver. The

additional polysaccharides may additionally or alternatively comprise any other medically acceptable polysaccharides, such as for example cellulose, regenerated celluloses such as rayon, non-anionic cellulose derivatives such as hydroxyethyl cellulose, and starch derivatives.

5

The wound dressing materials according to the present invention may further comprise anionic polysaccharides that have been complexed to therapeutically effective metal ions other than silver, for example bismuth, copper, nickel, zinc, manganese, magnesium, gold, or mixtures thereof. Preferably, the amounts of such polysaccharides complexed to other metals is from 0.001 to 10wt.% of the dressing, more preferably from 0.01 to 1wt% of the dressing. Preferably, the amounts of said other metals is from 10 to 10000ppm, more preferably from about 50 to about 1000ppm in the dressing.

10

15 The wound dressing materials according to the present invention may further comprise other medically acceptable materials besides polysaccharides, including textile fibers such as nylon or polyester staple fibers, nontextile fibers such as meltblown nylon fibers, and bioresorbable fibers such as polylactide/polyglycolide fibers. The other fibers may provide reinforcement and dilution of the polysaccharide. The other fibers are preferably present in an amount up to about 90wt%, more preferably from about 25% to about 75wt% of the wound dressing materials.

20

The wound dressing materials according to the present invention preferably further comprise collagen, in addition to the silver complex of an anionic polysaccharide. Preferably the amount of collagen in the dressing is from about 10% to about 90% by weight based on the dry weight of the wound dressing materials, more preferably from about 25% to about 75%.

25

30 The collagen may be selected from native collagens such as Types I, II or III native collagens, atelopeptide collagen, regenerated collagen and gelatin.

30

In certain embodiments, at least a portion of the collagen in the wound dressing materials is also complexed with silver. This can be achieved by treating the collagen with a solution of a silver salt. The silver salt may for example be silver acetate or silver nitrate at a concentration of about 0.01 molar to about 1 molar.

- 5 The treatment is preferably carried out at a pH of from about 5 to about 9. It is thought that the silver complexes primarily to the nitrogen-containing side chains of the collagen amino acids, in particular to lysine, hydroxylysine, asparagine, glutamine and arginine. The silver could also bind to the sulfhydryl groups of methionine and cysteine residues, where present, and to carboxyl groups of
- 10 aspartate and glutamate.

Preferably the amount of silver in the collagen complex is from about 0.01 to about 30% by weight based on the weight of the collagen, more preferably from about 0.1% to about 20%, more preferably from about 2% to about 10% by weight.

- 15 Preferably, the amount of silver-collagen complex in the wound dressing material is from about 0.1 to about 10 wt.%, more preferably from about 0.1 to about 2wt.%. In any case, the total amount of silver in the wound dressing material is generally as specified above.

- In certain embodiments the dressing according to the present invention is fully
- 20 resorbable. Preferably, the wound dressing materials according to the present invention are suitable for application directly to a wound surface.

- Preferred wound dressing materials according to the present invention are silver-containing versions of the dressings according to WO98/00180 or EP-A-1153622,
- 25 the entire contents of which are incorporated herein by reference. Briefly, these dressings are freeze-dried sponges that comprise a mixture of collagen and ORC, and that preferably consist essentially of such a mixture. Preferably, the weight ratio of collagen to ORC is about 40:60 to about 60:40. In the sponges according to the present invention, a portion of the ORC is replaced by a silver/ORC
- 30 complex, and/or a portion of the collagen may be replaced by a silver/collagen complex. Preferably, from about 0.1 to about 50wt.% of the ORC may be replaced by the silver-ORC complex, and a similar fraction of the collagen may similarly be

replaced. It will be appreciated that silver ion exchange can take place between the collagen and the ORC in such collagen/ORC wound dressing materials.

Especially suitable wound dressing materials are freeze-dried sponges comprising
5 from about 35wt% to about 60wt% of ORC, from about 60wt.% to about 35wt.% of a collagen, and from about 0.5% to about 5wt.% of an ORC/silver complex, wherein the complex comprises from about 10wt.% to about 40wt.% of silver based on the dry weight of the complex. In preferred embodiments, the materials comprise from about 0.5wt.% to about 2wt. % of the ORC/silver complex. In
10 preferred embodiments, the materials consist essentially of the collagen, ORC, and ORC/silver complex.

In another aspect, the present invention provides a wound dressing comprising a wound dressing material according to the invention. The wound dressing may
15 consist of, or consist essentially of the wound dressing material according to the invention.

The wound dressing is preferably in sheet form and comprises an active layer of the wound dressing material according to the invention. The active layer would
20 normally be the wound contacting layer in use, but in some embodiments it could be separated from the wound by a liquid-permeable top sheet. Preferably, the area of the active layer is from about 1cm² to about 400 cm², more preferably from about 4cm² to about 100cm².

25 Preferably, the article further comprises a backing sheet extending over the active layer opposite to the wound facing side of the active layer. Preferably, the backing sheet is larger than the active layer such that a marginal region of width 1mm to 50 mm, preferably 5mm to 20mm extends around the active layer to form a so-called island dressing. In such cases, the backing sheet is preferably coated with a
30 pressure sensitive medical grade adhesive in at least its marginal region.

Preferably, the backing sheet is substantially liquid-impermeable. The backing sheet is preferably semipermeable. That is to say, the backing sheet is preferably

permeable to water vapour, but not permeable to liquid water or wound exudate. Preferably, the backing sheet is also microorganism-impermeable. Suitable continuous conformable backing sheets will preferably have a moisture vapor transmission rate (MVTR) of the backing sheet alone of 300 to 5000 g/m²/24hrs, preferably 500 to 2000 g/m²/24hrs at 37.5 °C at 100% to 10% relative humidity difference. The backing sheet thickness is preferably in the range of 10 to 1000 micrometers, more preferably 100 to 500 micrometers.

The MVTR of the dressing according to the present invention as a whole is lower than that of the backing sheet alone, because the apertured sheet partially obstructs moisture transfer through the dressing. Preferably, the MVTR of the dressing (measured across the island portion of the dressing) is from 20% to 80% of the MVTR of the backing sheet alone, more preferably from 20% to 60% thereof, and most preferably about 40% thereof. It has been found that such moisture vapor transmission rates allow the wound under the dressing to heal under moist conditions without causing the skin surrounding the wound to macerate.

Suitable polymers for forming the backing sheet include polyurethanes and polyalkoxyalkyl acrylates and methacrylates such as those disclosed in GB-A-1280631. Preferably, the backing sheet comprises a continuous layer of a high density blocked polyurethane foam that is predominantly closed-cell. A suitable backing sheet material is the polyurethane film available under the Registered Trade Mark ESTANE 5714F.

25

The adhesive (where present) layer should be moisture vapor transmitting and/or patterned to allow passage of water vapor therethrough. The adhesive layer is preferably a continuous moisture vapor transmitting, pressure-sensitive adhesive layer of the type conventionally used for island-type wound dressings, for example, a pressure sensitive adhesive based on acrylate ester copolymers, polyvinyl ethyl ether and polyurethane as described for example in GB-A-1280631. The basis weight of the adhesive layer is preferably 20 to 250 g/m², and more preferably 50 to 150 g/m². Polyurethane-based pressure sensitive adhesives are preferred.

30

Further layers of a multilayer absorbent article may be built up between the active layer and the protective sheet. For example, these layers may comprise an apertured plastic film to provide support for the active layer in use, in which case
5 the apertures in the film are preferably aligned in register with the apertures in the hydrogel layer.

The dressing may further comprise an absorbent layer between the active layer and the protective sheet, especially if the dressing is for use on exuding wounds.
10 The optional absorbent layer may be any of the layers conventionally used for absorbing wound fluids, serum or blood in the wound healing art, including gauzes, nonwoven fabrics, superabsorbents, hydrogels and mixtures thereof. Preferably, the absorbent layer comprises a layer of absorbent foam, such as an open celled hydrophilic polyurethane foam prepared in accordance with EP-A-
15 0541391, the entire content of which is expressly incorporated herein by reference. In other embodiments, the absorbent layer may be a nonwoven fibrous web, for example a carded web of viscose staple fibers. The basis weight of the absorbent layer may be in the range of 50-500g/m², such as 100-400g/m². The uncompressed thickness of the absorbent layer may be in the range of from
20 0.5mm to 10mm, such as 1mm to 4mm. The free (uncompressed) liquid absorbency measured for physiological saline may be in the range of 5 to 30 g/g at 25°. Preferably, the absorbent layer or layers are substantially coextensive with the chitosan/ORC layer.

25 The wound facing surface of the dressing is preferably protected by a removable cover sheet. The cover sheet is normally formed from flexible thermoplastic material. Suitable materials include polyesters and polyolefins. Preferably, the adhesive- facing surface of the cover sheet is a release surface. That is to say, a surface that is only weakly adherent to the active layer and the adhesive on the
30 backing sheet to assist peeling of the hydrogel layer from the cover sheet. For example, the cover sheet may be formed from a non-adherent plastic such as a fluoropolymer, or it may be provided with a release coating such as a silicone or fluoropolymer release coating.

Preferably, the wound dressing materials and/or the wound dressings according to the present invention are sterile. Preferably, they are packaged in a microorganism-impermeable container. Preferably, the sterility assurance level is
5 better than 10^{-6} . Preferably, the dressing has been sterilized by gamma-irradiation.

In a further aspect, the present invention provides the use of a complex of an anionic polysaccharide with silver for the preparation of a wound dressing material
10 according to the present invention for the treatment of wounds, especially chronic wounds such as venous ulcers, decubitis ulcers or diabetic ulcers. Preferably, the treatment comprises applying the wound dressing material directly to the surface of the wound.

15 In a further aspect, the present invention provides a method of treatment of a wound, comprising applying to the wound a wound dressing material comprising an effective amount of a complex of an anionic polysaccharide and silver, whereby said complex is antimicrobially effective without exhibiting substantial antiproliferative activity against wound healing cells. Preferably, the wound
20 dressing material is also effective to reduce inflammation. The method is especially suitable for treatment of chronic wounds such as venous ulcers, decubitis ulcers or diabetic ulcers.

It has also been found that the materials according to the present invention are
25 surprisingly effective to inhibit the release of TNF- α from macrophages. This property is expected to render the materials effective in the treatment of inflammation. Accordingly, in a further aspect, the present invention provides the use of a complex of an anionic polysaccharide with silver for the preparation of a material comprising from about 0.1wt.% to about 3wt.% of silver for use in the
30 treatment of inflammation.

The complex of an anionic polysaccharide and silver contained in the materials of the present invention can be made by a method comprising the step of treating an anionic polysaccharide with a solution of a silver salt. Preferably, the solution is an aqueous solution.

5

Preferably, the anionic polysaccharide is substantially insoluble in water at pH7, and the treatment is therefore carried out on the polysaccharide in the solid state. For example, the polysaccharide may be in the form of solid fibers, sheet, sponge or fabric. In certain embodiments, the anionic polysaccharide is a salt and the
10 treatment therefore can be regarded as an ion exchange. In other embodiments, the anionic polysaccharide is at least partly in free acid form, in which case the silver salt is preferably a salt of a weak acid, for example silver acetate, whereby the anionic polysaccharide is at least partially neutralised by the silver salt. Similar processes are described in EP-A-0437095, the entire content of which is expressly
15 incorporated herein by reference.

The neutralization reaction can be carried out in water or alcohol alone but is preferably carried out in mixtures of water and alcohols. The use of a mixture of water and alcohol provides good solubility for the weak acid salts via the water,
20 and the alcohol prevents the anionic polysaccharide from excessively swelling, distorting and weakening during the neutralization. Thus the physical properties of the material are retained. Methanol is the preferred alcohol because many of the above-mentioned salts have good solubility in this alcohol in combination with water. Preferably, the alcohol to water ratio has a range of about 4:1 to 1:4 . If the
25 solution becomes too rich in alcohol, some salts may no longer be soluble particularly if the alcohol is other than methanol. If the solution becomes too rich in water, some swelling of the polysaccharide will occur as neutralization takes place and there will be some loss in physical properties such as in the tensile strength of the polysaccharide. Other useful alcohols include, for example, ethyl alcohol,
30 propyl alcohol and isopropyl alcohol.

The use of a mild neutralizing agent such as silver acetate allows for control of the degree of neutralization. Use of stoichiometric and chemically equivalent amounts

of neutralizing agent and carboxylic acid on the anionic polysaccharide does not produce a 100% neutralized polysaccharide as would be produced with strong irreversible reactions with bases such as sodium hydroxide, sodium carbonate, sodium bicarbonate and ammonium hydroxide.

5

Anionic polysaccharides behave as an ion exchanger and will pull out of solution the silver cation of any silver salt that is passed over them. The by-product of this exchange is an acid from the salt and by using a salt of a weak organic acid, a weak acid such as acetic acid is produced which does no damage to the polysaccharide. Using salts of strong acids such as sodium chloride or sodium sulfate produces hydrochloric acid or sulfuric acid by-products respectively, and these strong acids can cause damage such as depolymerization of the polysaccharide

15 When using silver salts of weak acids, the silver ion is exchanged for a proton on the polysaccharide and part of the salt is converted to weak acid. The mixture of acid and salt in the solution results in a buffered solution which maintains a fairly constant pH and controls the degree of neutralization. An equilibrium reaction is established whereby the silver ions are bound to the acid portion of the polysaccharide and also to the salt molecules. This partitioning of the silver ions prevents the neutralization of the polysaccharide from going to completion.

Using a stoichiometric amount of, for example, silver acetate brings about a 65-75% degree of neutralization of the carboxylic acid groups on an oxidized cellulose polymer. This control of pH by creating a self generating buffered solution and the use of methanol to control the swelling of the material, leads to a partially neutralized material in which the physical properties, e.g. tensile strength and shape of the polysaccharide, are preserved.

30 The amount of silver salt used is generally about equal to or up to twice the stoichiometric amount of carboxylic acid content of the polysaccharide. Alternatively, a second charge of a stoichiometric amount of silver salt can be used if the reaction is recharged with fresh solvent and salt after the first charge

reaches a constant pH. The material with elevated pH is then washed to remove the excess silver salt and ions therefrom.

It will be appreciated that the complexes obtainable by the methods described above may be used in the products and methods according to any aspect of the invention. More generally, any feature or combination of features that is described as preferred in connection with any one aspect of the invention or in connection with the above-described methods is also preferred in connection with every other aspect of the invention. Furthermore, any combination of the specific or preferred features disclosed herein is also encompassed within the scope of the disclosure.

A specific embodiment of the process and product according to the present invention will now be described further, by way of example, with reference to the accompanying drawings, in which:

Figure 1 shows antimicrobial effect against *Staphylococcus Aureus*, plotted as zone of inhibition in mm at 2 days, for a first range of wound dressing material materials;

Figure 2 shows antimicrobial effect against *Staphylococcus Aureus*, plotted as zone of inhibition in mm at 24 and 48 hours, for a second range of wound dressing material materials;

Figure 3 shows antimicrobial effect against *Pseudomonas Aeruginosa*, plotted as zone of inhibition in mm at 24 and 48 hours, for the second range of wound dressing material materials;

Figure 4 shows the effect on cell proliferation of extracts from a third range of wound dressing material materials;

Figure 5 shows antimicrobial effect against *Staphylococcus Aureus*, plotted as zone of inhibition in mm at 2 days, for a fourth range of wound dressing material materials;

Figure 6 shows the effect on cell proliferation of extracts from a fifth range of wound dressing material materials; and

Figure 7 shows a graph of TNF- α concentration against time for the following wound dressing materials incubated with lipopolysaccharides and monocyte macrophages: (A) a wound dressing material according to the invention, (B)

0.01M Silver acetate solution, (C) a freeze-dried collagen/ORC dressing without silver, and (D) a conventional wound dressing gauze.

Example 1

5

A complex of ORC with silver was prepared as follows.

A SURGICEL cloth (Johnson & Johnson Medical, Arlington) was milled using a rotary knife cutter through a screen-plate, maintaining the temperature below
10 60°C, to provide a fibrous ORC powder

Silver acetate powder (4.08g) was dissolved in 800mls of de-ionised water. After all the powder had dissolved to form a colourless, clear solution, the ORC milled fibers (5g) were added to this solution. The ORC was then allowed to react for
15 sixty minutes, or less if desired. The solution was then filtered and the fibers were collected and washed with either de-ionised water or alcohol. The silver complex of ORC was then allowed to dry at 37°C overnight or until the fibers were dry. To reduce the darkening of the final product the solution and reacted fibers were protected from the light throughout the reaction.

20

Examples 2-7

Freeze-dried collagen/ORC sponges suitable for use as wound dressing materials according to the invention were prepared as follows.

25

First, the collagen component was prepared from bovine corium as follows. Bovine corium was split from cow hide, scraped and soaked in sodium hypochlorite solution (0.03% w/v) to inhibit microbial activity pending further processing.

30

The corium was then washed with water and treated with a solution containing sodium hydroxide (0.2% w/v) and hydrogen peroxide (0.02% w/v) to swell and sterilize the corium at ambient temperature.

The corium splits then underwent an alkali treatment step in a solution containing sodium hydroxide, calcium hydroxide and sodium bicarbonate (0.4% w/v, 0.6% w/v and 0.05% w.v, respectively) at pH greater than 12.2, ambient temperature, and for a time of 10-14 days, with tumbling, until an amide nitrogen level less than 0.24mmol/g was reached.

The corium splits then underwent an acid treatment step with 1% hydrochloric acid at ambient temperature and pH 0.8-1.2. The treatment was continued with tumbling until the corium splits had absorbed sufficient acid to reach a pH less than 2.5. The splits were then washed with water until the pH value of corium splits reached 3.0-3.4.

The corium splits were then comminuted with ice in a bowl chopper first with a coarse comminution and then with a fine comminution setting. The resulting paste, which was made up in a ratio of 650g of the corium splits to 100g of water, as ice, was frozen and stored before use in the next stage of the process. However, the collagen was not freeze-dried before admixture with the ORC in the next stage.

The silver-ORC complex, unmodified milled ORC powder, and the required weight (according to solids content) of frozen collagen paste were then added to a sufficient amount of water acidified with acetic acid to obtain a pH value of 3.0 and a total solids content of 1.0%-2.0%, in the following proportions by weight:

- Example 2: 45% Silver-ORC / 55% Collagen
Example 3: 20% Silver-ORC + 15% ORC / 55% Collagen
Example 4: 10% Silver-ORC + 35% ORC / 55% Collagen
Example 5: 2% Silver-ORC + 43% ORC / 55% Collagen
Example 6: 1% Silver-ORC + 44% ORC / 55% Collagen
Example 7: 0.2% Silver-ORC + 44.8% ORC / 55% Collagen

The mixture was homogenized through a Fryma MZ130D homogenizer, progressively diminishing the settings to form a homogeneous slurry. The pH of the slurry was maintained at 2.9-3.1. The slurry temperature was maintained below 20°C, and the solids content was maintained at 1% ± 0.07.

5

The resulting slurry was pumped to a degassing vessel. Vacuum was initiated for a minimum of 30 minutes, with intermittent stirring, to degas the slurry. The slurry was then pumped into freeze-drier trays to a depth of 25mm. The trays were placed onto freezer shelves where the temperature has been preset to -40°C. The freeze-drier programme was then initiated to dry and dehydrothermally cross-link the collagen and ORC to form thick sponge pads.

On completion of the cycle, the vacuum was released, the freeze-dried blocks were removed, and were then split to remove the top and bottom surface layers, and to divide the remainder of the blocks into 3mm-thick pads. The step of splitting the freeze-dried blocks into pads was carried out with a Fecken Kirfel K1 slitter.

Finally, the pads were die-cut to the desired size and shape on a die-cutter, packaged, and sterilized with 18-29 KGy of cobalt 60 gamma-irradiation. Surprisingly, this irradiation does not cause significant denaturation of the collagen, which appears to be stabilized by the presence of ORC. The resulting freeze-dried collagen ORC pads had a uniform, white, velvety appearance.

25 Examples 8-11

Collagen/ORC sponges were prepared from unmodified ORC and from collagen, wherein a fraction of the collagen had been replaced by a collagen-silver complex, as follows.

30

Silver acetate powder (1.48g) was dissolved in 400mls de-ionised water with stirring and warming.

Collagen slurry (417g, containing 5g solids at the percentage solids in the slurry of 1.2%) was added to the silver acetate solution and allowed to react for ten minutes stirring gently (If the collagen was allowed to react for longer it become stringy and was difficult to re-slurry in acetic acid).

5

The solution was filtered using the funnel and filter paper and the solids rinsed with de-ionised water. Squeezed out excess liquid in the solid by gently pressing between two filter papers. The collagen solids were protected from the light during this step and all following steps.

10

The solids were made up to a weight of 417g using 0.05M acetic acid. The mixture was placed into an Industrial Waring Blender and blended until a smooth slurry was achieved again.

15 Freeze dried sponges were then made as described above for Examples 2-7, with unmodified ORC and with replacement of a fraction of the collagen by the silver-complexed collagen slurry. These examples were considered to fall within the scope of the present invention because the silver in the silver-collagen complexes will also complex and exchange with the ORC under the preparation conditions.

20

The following formulations were made:

Example 8: 55% Silver-Collagen / 45% ORC

Example 9: 45% Silver-Collagen + 10% Collagen / 45% ORC

25 Example 10: 30% Silver- Collagen + 25% Collagen / 45% ORC

Example 11: 15% Silver- Collagen + 40% Collagen / 45% ORC

Procedure 1

30 The bactericidal activity of the sponges prepared in Examples 2 to 7 was tested on *pseudomonas Aeruginosa* and *staphylococcus Aureus* by looking at zone of inhibition.

Six 2cm x 2cm squares of each sample were cut out in sterile conditions. On day one of the experiment cultures of both *Pseudomonas aeruginosa* and *Staphylococcus aureus* were incubated aerobically at 37°C for 24 hours on Diagnostic Sensitivity Agar (DSA). After 24 hours test samples were each placed
5 on a DSA plate and were immediately wetted with 0.5mls of a buffer solution. Three squares of sample were placed on plates inoculated with *Pseudomonas aeruginosa* and three were placed on plates inoculated with *Staphylococcus aureus*. The plates were then incubated at 37°C for 24 hours. The zone of inhibited growth around the sample was then measured using callipers and the
10 test sample was placed on a new inoculated DSA plate. A swab test was carried out on the area beneath the sample to determine if the sample was bacteriostatic if not bactericidal by smearing the swab on a DSA plate and incubating it for 24 hours and then examining the growth. The samples were transferred onto fresh inoculated plates with the above procedure being carried out every 24 hours for 72
15 hours as long as the samples remain intact.

As a negative control, a freeze dried sponge of 45%ORC/55%collagen without any silver was tested. A commercially available silver-containing antimicrobial dressing (ACTICOAT, registered trade mark of Smith & Nephew) and silver nitrate
20 solution (0.5%) were used as positive controls and zones of inhibition were observed for both over the test period.

Referring to Figures 1 and 2, it can be seen that significant bactericidal effects were observed against *Staphylococcus aureus* for the materials containing 1%
25 silver-ORC and above. The performance was comparable to that of the ACTICOAT dressing.

Referring to Figure 3, it can be seen that significant bactericidal effects were observed against *Pseudomonas Aeruginosa* for the materials containing 10%
30 silver-ORC and above. The performance at 24 hours was superior to that of the ACTICOAT dressing.

The bactericidal activity of the sponges prepared in Examples 8, 10 and 11 was tested on *Pseudomonas Aeruginosa* by looking at zone of inhibition in the same way as described above. Again, a 55%collagen/45%ORC sponge was used as a negative control, and silver nitrate solution (0.5%) and ACTICOAT were used as positive controls. The results at 48 hours were shown in Figure 5. It can be seen that the sponges made with collagen-silver complexes show similar zones of inhibition to the positive controls and to the silver-ORC examples of Fig. 3.

Procedure 2

10

The antiproliferative effects of the dressings from the above Examples were assessed as follows.

Prototype extracts were prepared as follows - 1mg of each wound dressing material to be tested was placed in 1ml of serum free medium and incubated for 24 hours at 37°C under sterile conditions.

Adult human dermal fibroblasts were grown and maintained in DMEM 10% FBS (standard culture medium; Dulbecco's minimal essential medium; foetal bovine serum). These cells were routinely subcultured and used for experimental testing when 95% confluent. Adult human dermal fibroblasts were harvested at 95% confluency and re-seeded in a 96-well microtitre plate (100µl/well) in DMEM + 10% FBS at a cell density of 2.5×10^4 cells/ml. Cells were allowed to adhere to the plate surface for 24 hours in a humidified incubator at 37°C, 5% CO₂. The medium was then removed by aspiration and the cell monolayer washed with serum-free DMEM. Test samples (extracts of each prototype) were then added to the cell monolayer (100µl/well), and 6 replicates of each concentration tested. Serum-containing growth medium (10% FBS in DMEM) was used as a positive control, and serum-free medium was used as a negative control. All samples were incubated with the cells for 48 hours at 37°C, 5% CO₂. After this incubation period the conditioned medium was removed by aspiration and replaced with a labelling solution from a commercial cell proliferation kit (XTT, Cell Proliferation kit II, Cat. No. 1 465 015, obtained from Boehringer Mannheim). Once this solution was

added an initial absorbance reading was obtained at 450nm, after which the microtitre plate was incubated at 37°C, 5% CO₂ and the absorbance monitored over 4 hours. The proliferative effect of each prototype was evaluated by comparing the absorbance readings measured against the positive and negative
5 controls.

As a positive control, a freeze dried sponge of 45%ORC/55%collagen without any silver was tested, since this was already known to promote fibroblast proliferation.

10 ACTICOAT was used as a negative control, since it was generally known that the effect of silver on cells in culture was toxic with cell death occurring at high concentrations.

The results shown in Figure 4 were very surprising. It can be seen that the
15 samples containing 0.2% and 1% of the silver-ORC complex strongly promote fibroblast proliferation. This effect was a least double that observed with collagen/ORC, alone which has been shown previously to stimulate cell proliferation. This stimulatory effect was apparently limited to lower concentrations of silver-ORC, as concentrations of 2% and above were detrimental to cell growth.
20 The ACTICOAT control in this experiment shows the expected negative effect on fibroblast proliferation.

Referring to Figure 6, it can be seen that the sample of collagen/ORC material made with 45%silver-collagen, 10% unmodified collagen, and 45% ORC (Example
25 9) was also stimulatory for fibroblast proliferation, but not as stimulatory as the collagen/ORC positive control.

Procedure 3

30 The anti-inflammatory potential of the wound dressing materials according to the invention was studied as follows.

Lipopolysaccharide (LPS) has been shown to induce TNF- α and IL-1 production in monocyte macrophage cells. This response can be used to assess anti-inflammatory potential of wound dressings, as TNF- α and IL-1 are known to potentate the inflammation process.

5

To assess the anti-inflammatory properties of the wound dressing materials, samples were incubated in the presence and absence of lipopolysaccharide (E.Coli 055.B5, Sigma Chemical Co.) with monocyte macrophages (THP-1 cells from the European Collection of Cell Cultures). As positive and negative controls,
10 various reference dressing materials and varying concentrations of silver acetate were also incubated with THP-1 cells in the presence and absence of LPS. The concentrations of silver acetate ranged from 0.01M to 0.001mM. Silver acetate is known to be cytotoxic at the highest concentrations in this range, and to have no cytotoxicity at the low end. The levels of both TNF- α and IL-1 produced by the
15 THP-1 cells were measured over a 24 hour time period after addition of LPS.

The following wound dressing materials were tested:

- (A) A freeze-dried sponge wound dressing material according to the present invention containing 1wt.% of a silver/ORC complex, prepared as described above
20 in Example 6;
- (B) A freeze-dried sponge consisting of 55 wt.% collagen and 45% ORC prepared as described in EP-A-1153622 and available under the Registered Trade Mark PROMOGRAN from Johnson & Johnson Wound Care (Control example); and
- 25 (C) A medical gauze available under the Registered Trade Mark SOF-WICK from Johnson & Johnson Wound Care (Control Example).

The experimental procedure was as follows.

- 30 The THP-1 cells were maintained in low LPS 10% FBS. Cells were then spun down at 1000rpm for 10 minutes and re-suspended to give a concentration of 10,000 cells per ml. PMA (Phorbol 12-myristate 13-acetate, Sigma Chemical Co.) was then added to the cell suspension to give a final concentration of 2.4×10^{-7} M.

This cell suspension was then used to seed 24 well microtiter plates with 10 000 cells/well. Plates were then incubated at 36°C, 5% CO₂ for 72 hours to allow adherence of cells to the tissue culture plastic.

- 5 RPMI medium containing 1mg/ml of LPS was then prepared. (LPS was reconstituted at 1mg/ml in sterile phosphate buffered saline). After incubation, the PMA medium on the 24 well microtitre plates was removed via aspiration and replaced with RPMI + LPS or RPMI medium alone.
- 10 6mm punch samples from the materials to be tested were removed and soaked in PBS for no more than 2 minutes. Two specimens of each dressing material type were sampled four times to give a total of eight samples for each dressing type. Silver acetate solutions were prepared in RPMI media to give concentration of 0.1M, 10mM, 1mM and 0.1mM.
- 15 The pre-soaked dressing biopsies and different concentrations of silver acetate were then added to the microtiter plate. 10µl of each silver acetate solution was added to each test wells giving test concentrations of 0.01M, 1mM, 0.1mM and 0.01mM.
- 20 The microtiter plates were then incubated at 37°C, 5% CO₂. After 4, 6 and 24 hours incubation 20µl aliquots of conditioned media were removed from each well. Samples were transferred to bullet tubes and stored at -70°C until ELISA analysis.
- 25 Before ELISA analysis media samples were divided into 10 µl aliquots and diluted 1:2 with calibrator diluent (calibrator diluent used depended on ELISA being performed). This dilution brought samples within the standard curve range. Manufacturer's instructions for the ELISA kits were followed. The ELISA kits were supplied by R&D Systems Limited.
- 30 Standard curves for both TNF-α and IL-1β were plotted and the equations generated were used to convert sample absorbencies to equivalent cytokine concentrations. Average concentrations of both TNF-α and IL-1β were calculated

for each sample condition at each time point. These results were then used to compare differences between test conditions over time.

At cytotoxic levels (0.01M) silver acetate induced cell death and therefore no TNF- α was produced. At sub-cytotoxic levels (0.1mM, and 0.001mM) the THP-1 cells remained viable (as determined by microscopic examination) and induced a dose response in the amount of TNF- α produced. 0.01mM silver acetate showed an ability to inhibit the amount of TNF- α produced, whilst the lowest concentrations of silver acetate studied had no effect on the amount of no TNF- α produced after stimulation with LPS.

Referring to Fig. 7, it can be seen that the various dressings tested demonstrated different abilities to influence the amount of TNF-alpha produced by THP-1 cells. Gauze (Sample C) had little effect, and cells in the presence of this dressing produced the same level of TNF- α as seen in the positive control (LPS only).

Cells in the presence of a silver-free collagen/ORC sponge dressing (Sample B) produced lower levels of the inflammatory cytokine than seen with LPS alone.

However, when a silver-containing collagen/ORC sponge dressing material according to the present invention (Sample A) was present in the assay well, THP-1 cells produced virtually no TNF- α . The inhibition by the material according to the present invention was, surprisingly, even better than that achieved with silver acetate concentrations (0.01mM) equivalent to those present in the material.

Results for IL-1 β (data not shown) were similar to those shown for TNF- α .

The results indicate an ability of the material according to the present invention to inhibit the production of important inflammatory cytokines by THP-1 monocyte macrophages. This effect was shown to be sustained throughout the 24 hour test period and suggests the material of the present invention has an ability to influence cytokine production over a prolonged time frame. The anti-inflammatory

activity of the material according to the present invention could not be predicted from the two components alone.


The Examples have been described for the purpose of illustration only. Many
5 other compositions and methods falling within the scope of the present invention will be apparent to the skilled reader.

CLAIMS

1. A wound dressing material comprising a complex of an anionic polysaccharide with silver, wherein the material comprises from about 0.1wt.% to
5 about 3wt.% of silver.
2. A wound dressing material according to claim 1, wherein the complex comprises a salt formed between the anionic polysaccharide and Ag^+ .
- 10 3. A wound dressing material according to claim 1 or 2, wherein the anionic polysaccharide is a polycarboxylate.
4. A wound dressing material according to any preceding claim, wherein the anionic polysaccharide is selected from the group consisting of alginates,
15 hyaluronates, pectins, carrageenans, xanthan gums, sulfated dextrans, cellulose derivatives, oxidized celluloses and mixtures thereof.
5. A wound dressing material according to any preceding claim, wherein the amount of silver in the complex is from about 1 to about 50% by weight based on
20 the weight of the anionic polysaccharide.
6. A wound dressing material according to claim 6, in the form of a freeze-dried sponge sheet, or a woven or nonwoven fibrous sheet, or a gel sheet.
- 25 7. A wound dressing material according to any preceding, wherein the wound dressing material comprises from about 0.1wt% to about 10wt% of the complex.
8. A wound dressing material according to any preceding claim, wherein the amount of silver in the wound dressing material is from more than about 0.1wt%
30 to about 2wt.%.

9. A wound dressing material according to any preceding claim, wherein the wound dressing material comprises collagen and oxidized regenerated cellulose (ORC) complexed with silver.
- 5 10. A wound dressing comprising a wound dressing material according to any preceding claim.
11. A wound dressing according to claim 10, wherein the wound dressing is sterile and packaged in a microorganism-impermeable container.
- 10 12. Use of a complex of an anionic polysaccharide with silver for the preparation of a material comprising from about 0.1wt.% to about 3wt.% of silver for use in the treatment of wounds.
- 15 13. Use according to claim 13, wherein said wounds are chronic wounds such as venous ulcers, decubitis ulcers or diabetic ulcers.
14. Use according to claim 12 or 13, wherein said treatment comprises applying said wound dressing material directly to the surface of the wound.
- 20 15. Use of a complex of an anionic polysaccharide with silver for the preparation of a material comprising from about 0.1wt.% to about 3wt.% of silver for use in the treatment of inflammation

FIG. 1



2/6

FIG. 2





FIG. 3



3/6

FIG. 4






FIG. 5




5/6

FIG. 6



6/6

FIG. 7



INTERNATIONAL SEARCH REPORT

International Application No
PC 03/03898

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L15/44 A61L15/28 A61L15/22 A61L26/00 A61L31/16
A61L31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 00180 A (WATT PAUL WILLIAM ; HARVEY WILSON (GB); LORIMER ELAINE (GB); JOHNSO) 8 January 1998 (1998-01-08) cited in the application page 5, line 19 - line 20; claims ---	1-15
X	WO 00 09173 A (LARSEN KIM LAMBERTSEN ; SAMUELSEN PETER BOMAN (DK); COLOPLAST AS (D) 24 February 2000 (2000-02-24) claims ---	1-15
X	WO 96 13282 A (INNOVATIVE TECH LTD ; QIN YIMIN (GB); GILDING KEITH DENNIS (GB)) 9 May 1996 (1996-05-09) claims; examples 1,2 ---	1-8
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

17 December 2003

Date of mailing of the international search report

30/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

ESPINOSA, M

INTERNATIONAL SEARCH REPORT

International Publication No
PCT/03/03898

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHOI Y S ET AL: "STUDIES ON GELATIN-BASED SPONGES. PART III: A COMPARATIVE STUDY OF CROSS-LINKED GELATIN/ALGINATE, GELATIN/HYALURONATE AND CHITOSAN/HYALURONATE SPONGES AND THEIR APPLICATION AS A WOUND DRESSING IN FULL-THICKNESS SKIN DEFECT OF RAT" JOURNAL OF MATERIALS SCIENCE. MATERIALS IN MEDICINE, CHAPMAN AND HALL, LONDON, GB, vol. 12, no. 1, 2001, pages 67-73, XP009007057 ISSN: 0957-4530 abstract	1-8
X	CHO Y-S ET AL: "HYALURONIC ACID AND SILVER SULFADIAZINE-IMPREGNATED POLYURETHANE FOAMS FOR WOUND DRESSING APPLICATION" JOURNAL OF MATERIALS SCIENCE. MATERIALS IN MEDICINE, CHAPMAN AND HALL, LONDON, GB, vol. 13, no. 9, 2002, pages 861-865, XP009007039 ISSN: 0957-4530 abstract	1,4,6
X	WO 02 24240 A (WOODS DAVID MALCOLM ;ACORDIS SPECIALTY FIBRES LTD (GB)) 28 March 2002 (2002-03-28) claims; examples 1,2	1-8
X	WO 02 36866 A (GROOCKOCK MELANIE RACHEL ;QIN YIMIN (GB); SSL INTERNAT PLC (GB)) 10 May 2002 (2002-05-10) claims	1-8
X	WO 01 24839 A (ACRYMED ;GIBBINS BRUCE L (US); HOPMAN LANCE D (US)) 12 April 2001 (2001-04-12) claims; examples	1-8
A	WO 01 24841 A (CULLEN BRED A MARY ;JOHNSON & JOHNSON MEDICAL LTD (GB); SILCOCK DER) 12 April 2001 (2001-04-12) claims; examples 1-3	1-15
A	GB 2 314 840 A (JOHNSON & JOHNSON MEDICAL) 14 January 1998 (1998-01-14) claims	1-15

INTERNATIONAL SEARCH REPORT

International application No
PCT/03/03898

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9800180	A	08-01-1998	GB 2314842 A AT 247493 T AU 737809 B2 AU 3269297 A BR 9710177 A CA 2258990 A1 CZ 9804251 A3 DE 69724257 D1 EP 1325754 A1 EP 0918548 A1 WO 9800180 A1 JP 2000513258 T KR 2000022287 A PL 330824 A1	14-01-1998 15-09-2003 30-08-2001 21-01-1998 18-01-2000 08-01-1998 12-05-1999 25-09-2003 09-07-2003 02-06-1999 08-01-1998 10-10-2000 25-04-2000 07-06-1999
WO 0009173	A	24-02-2000	AU 5153399 A WO 0009173 A1 EP 1104311 A1 US 6468521 B1	06-03-2000 24-02-2000 06-06-2001 22-10-2002
WO 9613282	A	09-05-1996	AU 3706695 A DE 69529298 D1 DE 69529298 T2 EP 0788378 A1 ES 2189830 T3 WO 9613282 A1 GB 2309909 A , B	23-05-1996 06-02-2003 06-11-2003 13-08-1997 16-07-2003 09-05-1996 13-08-1997
WO 0224240	A	28-03-2002	GB 2370226 A AU 8790601 A CA 2420150 A1 EP 1318842 A1 WO 0224240 A1 US 2003180346 A1	26-06-2002 02-04-2002 28-03-2002 18-06-2003 28-03-2002 25-09-2003
WO 0236866	A	10-05-2002	AU 1249102 A CA 2427752 A1 EP 1330565 A1 WO 0236866 A1 GB 2383047 A	15-05-2002 10-05-2002 30-07-2003 10-05-2002 18-06-2003
WO 0124839	A	12-04-2001	AU 7989100 A EP 1216065 A1 WO 0124839 A1 US 6605751 B1	10-05-2001 26-06-2002 12-04-2001 12-08-2003
WO 0124841	A	12-04-2001	GB 2354708 A AU 7538100 A EP 1216066 A1 WO 0124841 A1 JP 2003511099 T	04-04-2001 10-05-2001 26-06-2002 12-04-2001 25-03-2003
GB 2314840	A	14-01-1998	AT 195742 T AU 725296 B2 AU 3269397 A BR 9710003 A CA 2258849 A1 CZ 9804274 A3	15-09-2000 12-10-2000 21-01-1998 11-01-2000 08-01-1998 12-05-1999

INTERNATIONAL SEARCH REPORT

International Application No
PC 03/03898

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2314840	A	DE 69702911 D1	28-09-2000
		DE 69702911 T2	22-02-2001
		EP 0907664 A1	14-04-1999
		ES 2148991 T3	16-10-2000
		WO 9800446 A1	08-01-1998
		GR 3034853 T3	28-02-2001
		HU 9903404 A2	28-03-2000
		JP 2000514110 T	24-10-2000
		KR 2000022286 A	25-04-2000
		PL 330825 A1	07-06-1999
		PT 907664 T	29-12-2000